"For the primary endpoint, all dose groups of BTX 1503 reduced the number of inflammatory lesions from baseline with the highest efficacy obtained for the 5% BTX 1503 QD group (-11.8 lesions). This corresponds to an average percent reduction of 40.54%. The combined vehicle group result was -11.3 lesions or an average percent reduction of 40.15%."
Ann: Botanix Announces BTX 1503 Data and Progression to Phase 3, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
14.8¢ |
Change
-0.003(1.67%) |
Mkt cap ! $289.2M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.0¢ | 14.5¢ | $361.1K | 2.425M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 3172973 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 2131371 | 43 |
View Market Depth
| Last trade - 12.39pm 17/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |